comparemela.com

Latest Breaking News On - Bicara therapeutics - Page 4 : comparemela.com

Bicara Therapeutics Announces Publication in Cancer Research Describing Design and Characterization

CAMBRIDGE, Mass. (BUSINESS WIRE) Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the publication of a manuscript in Cancer Research, a journal of the American Association for Cancer Research (AACR), describ.

United statesUnited kingdomRachel salazarSarah mccabePradip nairChris raileyAmerican association for cancer researchSyngene internationalStern investor relations incCancer researchBicara therapeuticsAmerican associationAssociate research directorInvestor relations

Premji Invest leads Indian fintech platform Mintifi s $110m Series D round

Mintifi plans to use the funding to expand its presence across key sectors

Azim premjiSaravanan nattanmaiTata motorsWorld bank international finance corporationPremji investNorwest venture partnersWorld bankInternational finance corporationBicara therapeuticsKiran mazumdar shaw founded biocon

Bicara Therapeutics, a spinout of Kiran Mazumdar-Shaw s Biocon, raises $108m

The Series B round was co-led by Red Tree Venture Capital and RA Capital Management.

Bicara therapeuticsKiran mazumdar shaw founded bioconRed tree venture capitalEight roads venturesF prime capitalPiper heartland healthcare capitalOmega fundsBioqube venturesAcorn bioventuresJanus henderson

Bicara Therapeutics Raises $108M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United kingdomClaire mazumdarKetan patelJake simsonBicara therapeuticsRed tree venture capitalF prime capitalEight roads venturesPiper heartland healthcare capitalOmega fundsBioqube venturesAcorn bioventuresJanus hendersonKrishna polu

Bicara Therapeutics Presents New Data from Ongoing Phase 1/1b Trial of Lead First-in-Class Bifunctio

- Stage one efficacy threshold achieved in dose expansion in patients with squamous cell carcinoma of the head and neck- Webinar to review data to be held Monday, September 12th at 10:30 a.m. ET, featuring Principal Investigator Glenn J. Hanna, M.D.CAMBRIDGE, Mass. (BUSINESS WIRE) Bicara Therapeutics, a clinical-s.

United kingdomFrance generalSarah mccabeChris raileyLiviu niculescuGlennj hannaStern investor relations incDana farber cancer instituteEuropean society for medical oncologyPrincipal investigator glennBicara therapeuticsEuropean societyMedical oncologyRare headNeck cancersPrincipal investigator

vimarsana © 2020. All Rights Reserved.